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Abstract. The event-based model (EBM) for data-driven disease pro-
gression modeling estimates the sequence in which biomarkers for a dis-
ease become abnormal. This helps in understanding the dynamics of dis-
ease progression and facilitates early diagnosis by staging patients on a
disease progression timeline. Existing EBM methods are all generative in
nature. In this work we propose a novel discriminative approach to EBM,
which is shown to be more accurate as well as computationally more ef-
ficient than existing state-of-the art EBM methods. The method first
estimates for each subject an approximate ordering of events, by ranking
the posterior probabilities of individual biomarkers being abnormal. Sub-
sequently, the central ordering over all subjects is estimated by fitting a
generalized Mallows model to these approximate subject-specific order-
ings based on a novel probabilistic Kendall’s Tau distance. To evaluate
the accuracy, we performed extensive experiments on synthetic data sim-
ulating the progression of Alzheimer’s disease. Subsequently, the method
was applied to the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
data to estimate the central event ordering in the dataset. The experi-
ments benchmark the accuracy of the new model under various condi-
tions and compare it with existing state-of-the-art EBM methods. The
results indicate that discriminative EBM could be a simple and elegant
approach to disease progression modeling.
1 Introduction
Alzheimer’s Disease (AD) is characterized by a cascade of biomarkers becoming
abnormal, the pathophysiology of which is very complex and largely unknown.
However, understanding the progression of several imaging and clinical biomark-
ers after disease onset is extremely important for both early diagnosis and pa-
tient staging. Conventional models of disease progression reconstruct biomarker
trajectories in individual subjects using longitudinal data. This is done to get
insight into disease progression mechanism [9] [10]. However, the utility of such
models are restricted by the fact that longitudinal data in large groups of pa-
tients is scarce. To circumvent this problem, methods to infer the order in which
biomarkers for a disease become abnormal based on cross-sectional data have
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2been proposed [2] [5]. Some of these models [6] [5] rely on stratification of pa-
tients into several subgroups based on symptomatic staging, for inferring the
aforementioned ordering. However, the problem with using symptomatic staging
is that it is very coarse and qualitative.
Event based modeling (EBM) [2] [4] [12] is a data-driven approach to disease
progression modeling. EBM algorithms neither rely on symptomatic staging nor
on the presence of longitudinal data for inferring the temporal ordering of events,
where an event is defined by a biomarker becoming abnormal. All the variants
of EBM developed so far are generative in nature. The existing state-of-the-art
EBM methods are either not very robust in handling disease heterogeneity or
scalable to large number of biomarkers, as will be demonstrated in this paper.
In this work, we propose a novel discriminative approach to EBM (DEBM)
to address these issues. We assume that the event orderings for each subject
in the dataset need not be unique, but form a cluster around a single central
ordering. We first compute a noisy estimate of event ordering for each subject
by ranking the posterior probabilities of individual biomarkers being abnormal.
Subsequently, we introduce a novel probabilistic Kendall’s Tau distance to reli-
ably aggregate such noisy subject-specific event orderings to estimate a central
ordering over all subjects.
2 Event Based Models
The EBM considers disease progression as a series of events, where each event
corresponds to a new biomarker becoming abnormal. Fonteijn’s EBM [2] finds
the ordering of events (σ0) such that the likelihood that a dataset was generated
from subjects following this event ordering is maximized. This event ordering
(σ0) consists of a discrete set of events {Eσ0(1), Eσ0(2), ..., Eσ0(N)}, where N is
the number of biomarkers per subject in the dataset.
Given a cross-sectional dataset of M subjects, if Xj denotes a measurement
of biomarkers for each subject at a certain timepoint, with each measurement
Xj consisting of N biomarker values xj,i, the likelihood of the dataset being
generated by σ0 as defined by [2] is given by:
p (X|σ0) =
M∏
j=1
N∑
k=0
p(k)
(
k∏
i=1
p
(
xj,σ0(i)|Eσ0(i)
) N∏
i=k+1
p
(
xj,σ0(i)|¬Eσ0(i)
))
(1)
where p(k) is the prior probability of a subject being at position k of the event
ordering, which is assumed to be equal for each position. With the assump-
tion that all the biomarkers in the control population are normal and that the
biomarker values follow a Gaussian distribution, p
(
xj,σ0(i)|¬Eσ0(i)
)
is computed.
Abnormal biomarker values in the patient population are assumed to follow a
uniform distribution but not all biomarkers of a patient could be assumed to be
abnormal. For this reason, the likelihoods were obtained using a mixture model
of Gaussian-uniform distributions where only the parameters of the uniform dis-
tribution were allowed to be optimized.
3This method was slightly modified in [12] to estimate the optimal ordering in
a sporadic AD dataset with significant proportions of controls were expected to
have presymptomatic AD. A Gaussian distribution was used to describe both the
control and patient population, and the mixture model allowed for optimization
of parameters for the Gaussians describing both control and patient population.
Gaussian mixture model was also used to incorporate more subjects from the
dataset with clinical diagnosis of mild cognitive impairment (MCI).
An assumption made in [2] and [12] is the existence of a single ordering
common in all the subjects within a cohort. Such as assumption is rather too
restrictive for estimating the progression of a complex disease such as AD. This
assumption was relaxed in [4], which estimates a distribution of event orderings
with a central event ordering and a spread as per a generalized mallows model [8].
Huang’s EBM [4] is an expectation maximization algorithm to obtain the central
ordering σ0 and spread φ. The E-step estimates the likelihood of a patient’s
biomarker value measurement following an event order σj , given σ0 and φ. In
the M-step, σ0 and φ are estimated based on (σj) estimated in the E-step. This is
done iteratively to maximize the likelihood of generation of patients’ data based
on σ0 and φ.
While Fonteijn’s EBM is computationally inexpensive, the assumptions are
very restrictive. The assumptions in Huang’s EBM on the other hand are real-
istic, however the algorithm does not scale well to large number of biomarkers.
With these in mind, we propose a discriminative approach to EBM.
3 Discriminative Event Based Model
In this section, we propose our novel method for estimating central ordering of
events (σ0). We postulate that the posterior probability of a biomarker being
abnormal signifies the progression of a biomarker. Since this is done for each
biomarker measured from a subject, the different amounts of progression for
different biomarkers as estimated by their corresponding posterior probabilities
signify the event ordering in a subject (σj). However, the posterior probability
is not only affected by progression of the biomarker to its abnormal state, but
also by inherent variability in ‘healthy’ biomarker values across subjects, and by
measurement noise. Since it is not feasible to distinguish between these effects
based on a single (cross-sectional) measurement, we expect σj to be a noisy
estimate. To estimate σ0 based on noisy estimates of σj , we introduce a novel
variant of Kendall’s Tau distance which takes into account the posterior prob-
ability estimates. The proposed framework is discriminative in nature, since we
estimate σj directly based on the posterior probabilities of individual biomarker
becoming abnormal. This is in contrast to the existing EBM models, which es-
timates the event orderings based on the likelihood of the data being generated
by an ordering.
The rest of the section is organized as follows: Given a single cross-sectional
measurement of biomarkers from a subject, we present a method to estimate
4σj in Section 3.1. The problem of estimating σ0, from noisy estimates of σj is
addressed in Section 3.2.
3.1 Biomarker Progression and Subject-wise Event Ordering
Assuming a paradigm similar to that in previous EBM variants [4] [12], the prob-
ability density functions (PDF) of normal and abnormal classes in the biomarkers
are assumed to be represented by Gaussians. There are two reasons why con-
structing these PDFs is non-trivial. Firstly, the labels (clinical diagnoses) for
the subjects do not necessarily represent the true labels of all the biomarkers ex-
tracted from the subject. Not all biomarkers are abnormal for a subject with AD,
while some of the controls could have undiagnosed pre-symptomatic conditions.
Secondly, the clinical diagnosis is sometimes non-binary and includes classes such
as MCI, with significant number of biomarkers in normal and abnormal classes.
In our approach we address these two issues independently. We make an
initial estimate of the PDFs using biomarkers from ‘easy’ controls and ‘easy’
AD subjects and later refine the estimated PDF using the entire dataset.
A Bayesian classifier is trained for each biomarker using controls and AD
subjects, based on the assumption that there are no wrongly-labeled biomarker
in either class. This classifier is subsequently applied to the training data, and
the predicted labels are compared with the clinical labels. The misclassified data
in the training dataset could either be outliers in each class resulting from us-
ing untrustworthy labels or could genuinely belong to their respective classes
and represent the tails of the true PDFs. Irrespective of the reason of misclas-
sification, we remove them for initial estimation of the PDFs. This procedure
thus results, for each biomarker, in a set of ‘easy’ controls (whose biomarker
values represent normal values) and ‘easy’ AD subjects (whose biomarker values
represent abnormal values).
As we use Gaussians to represent the PDFs, we have initial estimates for
mean and standard deviation for both normal and abnormal classes for each
biomarker. We refine these estimates using a Gaussian mixture model (GMM)
and include all the available data, including MCI subjects and previously mis-
classified cases. The objective function for optimization for biomarker x:,i is:
Ci =
∑
j
log [(θi × p(xj,i|Ej,i)) + ((1− θi)× p(xj,i|¬Ej,i))] (2)
Where θi is the mixing parameter which determines the proportion of abnormal
biomarker data in the dataset and lies between [0, 1]. To obtain a robust GMM
fit, a constrained optimization method is used, putting bounds on the mean
and standard deviation parameters. These bounds are set to the 95% confidence
interval limits of the initial estimates of means and standard deviation.
The PDF thus obtained is used for classification of the biomarkers using a
Bayesian classifier where the mixing parameter θi is used as the prior probability
when estimating posterior probabilities for each biomarker. We assume these
posterior probabilities to be a measure of progression of a biomarker. Thus,
5sorting these biomarkers based on decreasing estimates of posterior probabilities
results in a noisy estimate for σj .
3.2 Estimating the Central Ordering
Since the event orderings for each subject are estimated independent of each
other, any heterogeneity in disease progression is captured in these estimates of
σj . The central event ordering (σ0) is the mean of the subject-specific estimates
of σj . To describe the distribution of σj , we make use of a generalized Mallows
model. The generalized Mallows model is parameterized by a central (‘mean’)
ordering as well as spread parameters (analogous to the standard deviation in a
normal distribution). The central ordering is defined as the ordering that mini-
mizes the sum of distances to all subject-wise orderings σj . To measure distance
between orderings, an often used measure is Kendall’s Tau distance [4]. Kendall’s
Tau distance between a subject specific event ordering (σj) and central ordering
(σ0) can be defined as:
K(σ0, σj) =
N−1∑
i=1
Vi(σ0, σj) (3)
where Vi(σ0, σj) is the number of adjacent swaps needed so that event at position
i is the same in σj and σ0.
Since the estimates of σj are based on rankings of posterior probabilities, it
would be desirable to penalize certain swaps more than others, based on how
close the posterior probabilities were to each other. To this end, we introduce
a probabilistic Kendall’s Tau distance, which penalizes each swap based on the
difference in posterior probabilities of the corresponding events. The probabilistic
Kendall’s Tau is computed sequentially using the following algorithm:
Algorithm 1 Probabilistic Kendall Tau distance between Event Orderings
1: for i ∈ {1, N − 1} do
2: k ← σ−1j (σ0(i))
3: if k > i then
4: Vi(σ0, σj)← p
(
Ej,σ0(k)|xj,σ0(k)
)− p (Ej,σ0(i)|xj,σ0(i))
5: Move σj(k) to position i and update σj
6: else
7: Vi(σ0, σj)← 0
This variant of Kendall’s Tau distance is quite close to the weighted Kendall’s
Tau distance defined in the permutation space introduced in [7]. The differene
stems from the fact that since the probabilistic Kendall’s Tau distance is between
individual estimates and a central-ordering, the penalization of each swap is
weighted assymetrically as Vi(σ0, σj) 6= Vi(σj , σ0). This asymetrical weighing
6can be formulated as a special case of the aforementioned weighted Kendall’s
Tau distance.
Computing a global optimum for the central ordering based on subject-wise
orderings is NP-hard. The optimization algorithm used in our implementation is
based on algorithm introduced by Fligner et. al. [8] to make an unbiased estimate
of the central ordering.
4 Experiments
This section describes the experiments performed to benchmark the accuracy
of the proposed DEBM algorithm and compare it with state-of-the-art EBM
methods. We begin with the details of the experiments performed on ADNI
data to estimate the event ordering in Section 4.1. Such an event ordering serves
as a timeline for disease progression and is used for patient staging. Since the
groundtruth event ordering is unknown for clinical datasets, we resort to using
accuracy of patient staging as an indirect way of measuring the reliability of the
event ordering. We also measure the accuracy of event ordering in a much more
direct way by performing extensive experiments on synthetic data simulating
the progression of AD. The details of these experiments are given in Section 4.2.
4.1 ADNI Data
We considered 509 ADNI1 subjects (162 healthy controls, 210 MCI and 137 AD
subjects) who had a 1.5T structural MRI (T1) scan at baseline. The T1w scans
were non-uniformity corrected using the N3 algorithm [11]. This was followed by
multi-atlas brain extraction using the method described in Bron et al. [1]. Multi-
atlas segmentation was performed using the structural MRI scans to obtain a
region-labeling for 83 brain regions in each subject using a set of 30 atlases [3].
We calculated the volume of these regions and used the ratio of these volumes
with the intra-cranial volume as biomarkers. This is done to compensate for the
inter-subject variability in head size. We also downloaded CSF (Aβ1−42, tau and
p-tau) and cognitive scores (MMSE, ADAS-Cog, RAVLT) biomarker values from
the ADNI database. Out of these, volume based biomarkers of 41 regions, 3 CSF
and 3 cognitive scores were found to be significant features based on Student’s
t-test with p < 0.01. These biomarker values were used to perform three sets of
experiments.
Experiment 1: A subset of 7 biomarkers including the 3 CSF features,
MMSE scores, ADAS-Cog scores, volume of the hippocampus and whole brain
was created. Event ordering of these 7 biomarkers was inferred using DEBM,
Huang’s EBM [4] and the variant of Fonteijn’s EBM that is suited for AD dis-
ease progression modeling [12]. The original Fonteijn’s EBM [2] differs from the
version in [12] only in the way in which normal and abnormal biomarker dis-
tributions are estimated. As an indirect way of measuring the reliability of the
1 http://adni.loni.usc.edu/
7estimated event ordering, we use patient staging based on the estimated event
orderings as a way to classify controls and AD subjects in the database. 10-fold
cross validation was used for this purpose. AUC measures were used to measure
the performance of these classifications and thus indirectly hint at the reliability
of the event ordering based on which the corresponding patient staging were
performed. We used the patient staging algorithm described in [2] for all three
EBMs to ensure that the difference in obtained AUC is strictly because of the
obtained event ordering.
Experiment 2: The above experiment was repeated for the entire set of 47
features. This was done to study the scalability of EBM techniques.
Experiment 3: We studied the positional variance of central ordering in-
ferred by DEBM by creating 100 bootstrapped samples of the data with 7
biomarkers followed by computing the central ordering for each of those samples.
4.2 Simulation Data
We use the framework developed by Young et al. [13] for simulating cross-
sectional data consisting of scalar biomarker values for healthy controls, MCI
and AD subjects. In this framework, disease progression in a subject is indi-
cated by a cascade of biomarkers becoming abnormal and individual biomarker
trajectories are represented by a sigmoid. The equation for generating biomarker
values for different subjects is given below:
xj,i(Ψ) =
1
1 + exp(−ρj,i(Ψ − ξj,i)) + βj,i (4)
ρj,i signifies the rate of progression of a biomarker with disease state Ψ . ξj,i
denotes the disease state at which a biomarker becomes abnormal. βj,i denotes
the value of the biomarker when the subject is normal. We assume ρj,i to be equal
for all the subjects, for all the biomarkers. With this assumption, variability in
a population while simulating a cross-sectional dataset could arise because of
variation in either β or ξ. Variation in ξj,i results in variation in ordering. In
our experiments, β and ξ are assumed to be Normal random variables Nβ and
Nξ respectively. Mean of Nβ is equal to the mean value of the corresponding
biomarker in the controls of the selected ADNI data. We vary relative standard
deviation of Nβ (Σβ) in our experiments, where 1 refers to the expected variation
among healthy controls, estimated based on the selected subjects in ADNI data.
Mean of Nξ for various biomarkers were assumed to be equi-spaced on the Ψ
scale. Standard deviation of Nξ (Σξ) is varied in multiples of ∆ξ/N , where ∆ξ
is the difference between mean of Nξ between adjacent biomarkers.
Using this simulation framework, we study the effect of these two factors
in the ability of different variants of EBM algorithms to accurately infer the
ground-truth central ordering in the population. Inaccuracy is computed based
on the normalized Kendall’s Tau distance between the ground truth ordering and
most-likely ordering (for Fonteijn’s EBM) or central ordering (for DEBM and
Huang’s EBM). As the Kendall’s Tau distance penalizes pair-wise disagreements
8between event agreements, a normalization factor for
(
N
2
)
, whereN is the number
of events, was chosen to make the accuracy measure interpretable for different
number of biomarkers.
We performed three sets of experiments on simulated data to study the accu-
racy of the different variants of EBM techniques and several aspects associated
with it. For all the experiments, the number of simulated subjects was taken to
be equal to the number of subjects in the selected ADNI data.
Experiment 4: The first experiment was based on selecting a subset of 7
biomarkers from the 47 significant biomarkers and study the effect of variation
of β and ξ. For each simulation setting, 50 repetitions of simulation data were
created and used for benchmarking the accuracies of DEBM, Huang’s EBM and
Fonteijn’s EBM.
Experiment 5: The above experiment was repeated for the entire set of 47
features. This was done to study the scalability of EBM techniques.
Experiment 6: The first experiment was repeated for DEBM and Fonteijn’s
EBM. In addition to these methods, accuracy of the method using DEBM with
normal Kendall’s Tau distance and Fonteijn’s EBM with the normal and ab-
normal biomarker distributions estimated based on the method discussed in
Section 3.1 were computed. This was done to ascertain the contributions of in-
dividual novel aspects of the proposed algorithm.
5 Results and Discussions
5.1 ADNI Data
The plots in Figure 1 (a) shows the AUC measures in the 10-folds of cross
validation. The different methods mentioned in the plot indicate the method used
for obtaining the event ordering based on which patient staging was done. The
results on the left and right side of the graph are for the case of 7 biomarkers and
47 biomarkers respectively. It must be noted that, in the absence of groundtruth
event ordering, results using clinical data only provide circumstantial evidence
about the reliability of the method and do not unambiguously prove that one
method is better than the other. It can be observed that DEBM based patient
staging outperforms both Fonteijn’s EBM and Huang’s EBM based staging,
when used as a classifier. The reduction in AUC while using 47 biomarkers
as compared to 7 biomarkers indicates that the set of 47 biomarkers is not
optimum for the purpose of classification and an optimum subset selection might
be required if this is indeed meant to be used as a classifier. However, as the
purpose here is to understand the disease progression mechanism, the decrease
in AUC values is not of much significance. The decrease in AUC measure for
Huang’s EBM is much more than the other two EBMs, when the number of
biomarkers increases. This indicates that Huang’s EBM might not be scalable.
The plots in Figure 1 (b) shows the positional variance diagram of the cen-
tral ordering while using 100 sets of bootstrapped samples. Uncertainty in the
estimation of central ordering can be observed in this diagram.
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Fig. 1: (a) AUC measures in the 10-folds of cross validation for 7 events and 47
events. (b) Positional variance diagram of the central ordering
Fig. 2: Effect of Σβ and Σξ in the mean inaccuracies of DEBM, Fonteijn’s EBM
and Huang’s EBM. Inaccuracies are measured by the distance of estimated event
ordering from the groundtruth ordering. These distances are represented based
on the shown colormap.
5.2 Simulation Data
Figure 2 shows the variation of mean inaccuracies of DEBM, Fonteijn’s EBM
and Huang’s EBM while varying Σβ and Σξ of biomarkers. Figures 3 (a) and
(b) depicts the variation of inaccuracies for 50 repetitions of simulated data for
the case of 7 biomarkers and 47 biomarkers respectively. In Figure 3 (a) for the
graph on the left, Σξ was fixed to a value of 2/7, while varying Σβ . For the
graph on the right, Σβ was fixed to be 1 and Σξ was varied from 0 to 4/7 in
steps of 1/7. Similarly, in Figure 3 (b) for the graph on the left, Σξ was fixed
to a value of 12/47, while varying Σβ . For the graph on the right, Σβ was fixed
to be 1 and Σξ was varied from 0 to 24/47 in steps of 6/47. Figures 2, 3 (a)
and (b) show that DEBM outperforms the state-of-the-art EBM techniques in
recovering the order in which biomarkers become abnormal. It can also be seen
that, while the performance of DEBM and Fonteijn’s EBM was similar for 7
and 47 biomarkers, the performance of Huang’s EBM degrades with increasing
number of biomarkers.
Figure 4 shows the results for Experiment 6 detailed in Section 4.2. It can be
seen that DEBM with probabilistic Kendall’s Tau distance outperforms DEBM
10
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Fig. 3: Variation in inaccuracies of DEBM, Fonteijn’s EBM and Huang’s EBM
for 50 repetitions of simulations. The number of events is 7 in (a) and 47 in (b).
Fig. 4: Variation in inaccuracies of DEBM, DEBM with Kendall’s Tau, Fonteijn’s
EBM and Modified Fonteijn’s EBM with respect to Σβ , with Σξ = 2/7.
with normal Kendall’s Tau distance. Fonteijn’s EBM using normal and abnormal
biomarker distributions computed using the technique proposed in Section 3.1
outperforms conventional Fonteijn’s EBM. It is also interesting to note that
DEBM outperforms the modified Fonteijn’s EBM as well, which uses the same
biomarker distribution estimation algorithm as DEBM.
Figure 5 shows the mean computation time (in seconds) for the three meth-
ods in logarithmic scale. The implementation for all the methods were done in
Python and measured in the same computer. DEBM is several orders of magni-
tude faster than Huang’s EBM and comparable to Fonteijn’s EBM.
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Fig. 5: Computation Time (in seconds)
6 Conclusion and Future Work
We proposed a novel discriminative EBM framework to estimate the ordering
in which biomarkers become abnormal during disease progression, based on a
cross-sectional dataset. The proposed framework outperforms state-of-the-art
EBM techniques in estimating the event ordering and is computationally very
efficient as well. In addition to the framework, we also proposed a novel prob-
abilistic Kendall’s Tau distance metric and a biomarker distribution estimation
algorithm. Each aspect of the proposed algorithm was ascertained to contribute
positively in improving the accuracy of estimation.
Fonteijn’s EBM assumes a unique event ordering that is common to all the
subjects in the database. When this assumption fails, the performance of the al-
gorithm degrades. Huang’s EBM and DEBM account for this variation. However,
Huang’s EBM estimates a lot of parameters through optimization for inferring
the central ordering, whereas DEBM is much more direct in estimating the cen-
tral ordering. This might be one of the reasons why DEBM outperforms Huang’s
EBM consistently. Moreover, the simplicity of the DEBM algorithm is crucial
for its scalability to large number of biomarkers.
Many possible extensions of the work are interesting to consider. Huang’s
EBM was extended to estimating clusters of central orderings in [13] using
Dirichlet process mixtures of generalized Mallows models. Such an extension is
also possible using DEBM. Subject-specific event orderings estimated based on
cross-sectional data are very noisy. Incorporating longitudinal data to get better
estimates of subject-specific event orderings in DEBM is also worth considering.
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